The Ophthalmic drug industry grosses over $1.8 billion Canadian annually and is the fastest growing segment of the Canadian pharmaceutical industry. Genix’s plan in the future is to research ocular herbal products and acquire an additional 70-100 ophthalmic drug products over the next 3 years.
GENX Chart by TradingView
Issued & Outstanding
Fully diluted common shares
Warrants & Options
For detailed financials, please visit SEDAR
Research and Development and Future Outlook
- Developing novel products for topical treatment of Age Related Macular Degeneration (ARMD) and eye strain, as well as various products for eye related diseases
- Continuing to build a pipeline of generic prescription drugs as Genix anticipates to increase the portfolio size from 30 generics to an additional 40 to 50 dossiers
Stay In Touch
Trade Alert – Delivering the latest product trends and industry news straight to your inbox.